BioNTech’s leadership handover arrives just as guidance tightens

BioNTech is entering a stretch where the story is being reshaped on two fronts at once: the numbers and the leadership. On Monday, the Mainz-based company said Guido Oelkers will take over as chief executive by 1 February 2027 at the latest, while the market is also digesting a lower outlook for 2026. The shares closed at EUR 80.20 on Monday in Xetra trading, up 2.17 percent on the day, and were later cited at EUR 77.60 on the reporting day, leaving the stock well below its 2026 peak of EUR 105.80.

The succession closes a long chapter. Ugur Sahin, who co-founded BioNTech and has led the group for around a decade and a half, will step down together with his wife and chief medical officer Özlem Türeci at the end of 2026. The couple plans to build a new mRNA company outside BioNTech. The supervisory board has already named Oelkers as Sahin’s successor, though the handover itself still lies ahead.

Oelkers brings deep pharmaceutical experience to the job. He has been chief executive of Swedish Orphan Biovitrum, or Sobi, since 2017, and BioNTech says he more than quadrupled that company’s revenue in that period. He has also previously run BSN Medical, Gambro and Invida. One key position remains unresolved: the company has not yet found a successor to Türeci as chief medical officer.

The timing matters because BioNTech is also trying to steer a costly transition away from the Covid vaccine business and toward oncology. The company cut its 2026 revenue forecast to EUR 1.6 billion to EUR 1.9 billion. Adjusted research and development expenses are expected at EUR 2.0 billion to EUR 2.3 billion, while adjusted selling and administrative costs stay unchanged at EUR 700 million to EUR 800 million.

That guidance reset comes against a still-difficult commercial backdrop. Analysts had already expected weakness tied to the decline in Covid vaccine sales, with the market consensus for the second quarter of 2026 pointing to a loss of USD 2.08 per share, wider than the USD 1.60 loss in the same period a year earlier. They had also been looking for a 40 percent year-on-year drop in Covid vaccine revenue.

BioNTech’s balance sheet remains a major counterweight. The company ended up with cash and securities worth EUR 16.6 billion, giving it room to fund the pipeline shift without depending on near-term revenue swings. That financial strength is part of the reason the market has not yet abandoned the stock’s longer-term case.

Should investors sell immediately? Or is it worth buying BioNTech?

There has also been a recent regulatory boost. Last week, the European Commission approved BioNTech and Pfizer’s Covid vaccine adapted to the XFG variant. The shot is authorised for people aged six months and older across all 27 EU member states and in Iceland. A strong autumn vaccination season could soften part of the sales decline.

At the same time, the strategic shift is becoming more visible in the cost base and operations. In May, BioNTech announced the closure of several manufacturing sites, including facilities in Idar-Oberstein, Marburg and Singapore, as well as former Curevac sites. Up to 1,860 jobs are affected. The moves reflect sharply lower demand for Covid vaccines and a reallocation of production capacity toward the oncology pipeline.

That oncology push is the core of the investment case. BioNTech wants to secure multiple cancer therapy approvals by 2030. A central asset in that plan is its partnership with Bristol Myers Squibb around the PD-1/VEGF bispecific antibody Pumitamig, also known as BNT327. Data presented at the ASCO congress in June from a phase 2 study showed a confirmed objective response rate in more than half of patients with squamous NSCLC.

For the shares, the technical picture is still mixed. The RSI stands at 41.3, which suggests the stock is not yet oversold. At the same time, it is trading below all important moving averages and remains in a clear downtrend. The 52-week low of EUR 68.35, reached in March, is still a reference point if sentiment weakens again.

BioNTech’s market value is currently EUR 19.90 billion. The average analyst price target of EUR 107.12 implies upside of about 38 percent from the current level, suggesting that many in the market still view the current weakness as temporary rather than structural. The next scheduled catalyst is the company’s third-quarter 2026 report on 3 November 2026.